NFTRH has been bearish on Doctor Copper for years due to the pattern and the bear flags it had a habit of making. Then last year when it broke the neckline we were able to add a target. So far, so good for 1.50/lb. The critical bear flag to test the breakdown failed over the…
Desperate bankers are attacking millennials with ever more frequency. They are doing so to get them to move out of the houses of their parents. Bankers cannot make real money unless they lend on houses. Millennials, or at least a large percentage of them, do not show an interest in home ownership at all. If…
Q2 Worker Pay Increase Smallest On Record
For the past few weeks, Greece’s flirtation with default has dominated the headlines – and for good reason. The danger to international markets is very real. But for American income investors, a default closer to home could prove even more disastrous. Should Puerto Rico default on $72-billion worth of municipal bond debt, it would hit…
You’re new to investing and want to pursue a small cap value strategy. You’ve read that value stocks and small caps tend to outperform over time and you, of course, would like to outperform. Looking back at history, following such a strategy seems like an easy ride. An investment of $10,000 in 1979 would have…
This past week we released our economic forecast for August which is indicating the weakest growth since 2010. There are forces working against economic expansion on Main Street. Also this past week, there was a major decline in the Conference Board Consumer Confidence index. What caused this decline? Consider that Main Street does not react…
Amid the collapse in commodities, crashing Chinese stocks, the weakest US wage growth in US history, and a data-dependent Fed; Goldman Sachs (GS) fears the new normal is ‘shorter-and-faster’ business cycles with no persistence primed by monetary policies. Most worryingly, they conclude, will short business cycles beget shorter business cycles? As Goldman notes, Cycles:…
Deals and Financings Boehringer Ingelheim will pay $50 million upfront and as much as $680 million in milestones for exclusive rights to a novel lung cancer treatment developed by Korea’s Hanmi Pharma (see story). BI will have global rights (except South Korea, China and Hong Kong) to HM61713, a novel 3rd generation EGFR targeted therapy….
Photo Credit: Gianni A few days ago, I was trying to buy a little bit of a defense company that I own for myself and clients. It was relatively inexpensive, and had fallen out of favor. Now, it’s not the most liquid beastie on the US market, so I put in an order to buy…
